ClinicalTrials.gg
Not yet recruitingNCT06091722Updated Oct 19, 2023

Quantitative Assessment of Lid Margin Vascularity Using SS-OCTA

An observational study in Ss-octa, Lid Margin Blood Flow Density and MGD, sponsored by Wenzhou Medical University. Not yet recruiting. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-19.

Sponsored by Wenzhou Medical University · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 11 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
150
Ages
20 Years and older
Sex
All
01

Study summary

To explore an optimized scan technique for the detection of lid margin vasculature

Read the detailed description

To investigate whether the SS-OCTA tool has the potential to characterize the lid margin vascularity in MGD patients. The repeatability and validity of OCTA in assessing eyelid margin blood flow density was evaluated。

02

Conditions studied

  • Ss-octa
  • Lid Margin Blood Flow Density
  • MGD
03

In context

Lead sponsor

Wenzhou Medical University is the lead sponsor of 94 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

MGD or normal patients who could cooperate with dry eye evaluation and SSOCTA examination in the dry eye Clinic of the Eye Hospital of Wenzhou Medical University were enrolled.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The MGD patients were aged >_20 years and were diagnosed according to Chinese MGD diagnostic criteria,11 including dry eye symptoms, and at least one of the following signs: (1) poor meibum expressibility or quality; (2) at least one of eyelid margin abnormalities (lid margin irregularity, plugging of the gland orifice, vascular engorgement/telangiectasia, and anterior replacement of the mucocutaneous junction. Normal subjects were defined as adults without any dry eye symptoms and lid margin abnormality.

Exclusion criteria

Exclusion Criteria:

(1) subjects with ocular diseases or conditions known to affect the anatomy of the anterior segment, such as acute ocular inflammation, a history of eyelid surgery, contact lens wear within two weeks, and/or eyelid trauma; (2) subjects with of history of systemic or topical medications that might cause ocular congestion; (3) subjects with severe systemic illness or pregnancy; and (4) subjects who were difficult to cooperate with examination, resulting the obtained images were not sufficiently clear for automatic analysis.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • 1

    Mild group, the scores of both clinicians were ≤ grade 1

  • 2

    Moderate group, one doctor scored grade 2, and the other doctor scored 1\~2;

  • 3

    Moderate group, one doctor scored grade 2, and the other doctor scored 1\~2;

06

What researchers measure

Primary outcomes

  1. LMBFD

    Lid margin blood flow density

    Time frame: Immediately after ssocta

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06091722
Lead sponsor
Wenzhou Medical University
Responsible party
Yune Zhao (Principal Investigator, Wenzhou Medical University) — Principal investigator
First posted
Oct 19, 2023
Start date
Oct 20, 2023 (estimated)
Primary completion
Dec 1, 2023 (estimated)
Completion
Feb 28, 2024 (estimated)
Last update
Oct 19, 2023

Study contacts

Man HU
Contact
64344308@qq.com
13738069080

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion